NCT03637205

Brief Summary

The aim of the study is to examine whether treatment with extracorporeal life support (ECLS) in addition to revascularization with percutaneous coronary intervention (PCI) or alternatively coronary artery bypass grafting (CABG) and optimal medical treatment is beneficial in comparison to no ECLS in patients with severe infarctrelated cardiogenic shock with respect to 30-day mortality

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
420

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jun 2019

Longer than P75 for not_applicable

Geographic Reach
2 countries

46 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 13, 2018

Completed
4 days until next milestone

First Posted

Study publicly available on registry

August 17, 2018

Completed
10 months until next milestone

Study Start

First participant enrolled

June 20, 2019

Completed
3.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 23, 2022

Completed
1.7 years until next milestone

Study Completion

Last participant's last visit for all outcomes

September 2, 2024

Completed
Last Updated

December 13, 2024

Status Verified

December 1, 2024

Enrollment Period

3.5 years

First QC Date

August 13, 2018

Last Update Submit

December 12, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • 30-day mortality

    30-day all-cause death after randomization according to the intention-to-treat principle

    30 days

Secondary Outcomes (17)

  • Time to death within 6 and 12 months follow-up

    6 and 12 months

  • Length of mechanical ventilation

    0 to 10 days

  • Time to hemodynamic stabilization

    0 to 10 days

  • Duration of catecholamine therapy

    0 to 10 days

  • Serial creatinine-level and creatinine-clearance

    0 to 10 days from time of randomization until stabilization

  • +12 more secondary outcomes

Study Arms (2)

ECLS

EXPERIMENTAL

PCI (or CABG) plus medical treatment + ECLS

Procedure: ECLS insertionOther: Revascularisation and optimal medical treatment

No ECLS

ACTIVE COMPARATOR

PCI (or CABG) plus medical treatment

Other: Revascularisation and optimal medical treatment

Interventions

After diagnostic angiography the culprit lesion should be identified and revascularization (preferably by PCI, alternatively CABG) should be planned. ECLS insertion should be performed preferably before revascularization

ECLS

After diagnostic angiography the culprit lesion should be identified and revascularization (preferably by PCI, alternatively CABG) should be planned.

ECLSNo ECLS

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Cardiogenic shock complicating AMI (STEMI or NSTEMI) plus obligatory:
  • Planned revascularization (PCI or alternatively CABG)
  • Systolic blood pressure \<90 mmHg \>30 min or catecholamines required to maintain pressure \>90 mmHg during Systole
  • Signs of impaired organ perfusion with at least one of the following criteria a) Altered mental Status, b) Cold, clammy skin and extremities, c) Oliguria with urine output \<30 ml/h
  • Arterial lactate \>3 mmol/l
  • Informed consent

You may not qualify if:

  • Resuscitation \>45 minutes
  • Mechanical cause of cardiogenic shock
  • Onset of shock \>12 h
  • Severe peripheral artery disease with impossibility to insert ECLS cannulae
  • Age \<18 years or age \>75 years
  • Shock of other cause (bradycardia, sepsis, hypovolemia, etc.)
  • Other severe concomitant disease with limited life expectancy \<6 months
  • Pregnancy
  • Participation in another trial

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (46)

Universitätsklinikum Aachen

Aachen, 52074, Germany

Location

Zentralklinik Bad Berka GmbH

Bad Berka, 99438, Germany

Location

SLK-Kliniken Heilbronn GmbH Klinikum Am Plattenwald

Bad Friedrichshall, 74177, Germany

Location

Kerckhoff-Klinik Forschungsgesellschaft mbH

Bad Nauheim, 61231, Germany

Location

Charité Universitätsmedizin Berlin, CBF Medizinische Klinik für Kardiologie

Berlin, 12203, Germany

Location

BG Klinikum Unfallkrankenhaus Berlin gGmbH

Berlin, 12683, Germany

Location

Universitätsklinikum Köln Klinik III für Innere Medizin

Cologne, 50937, Germany

Location

St-Johannes-Hospital Klinik für Innere Medizin I

Dortmund, 44137, Germany

Location

Technische Universität Dresden

Dresden, 01062, Germany

Location

Universitätsklinikum Düsseldorf Klinik für Kardiologie, Pneumologie und Angiologie

Düsseldorf, 40225, Germany

Location

Helios Klinikum Erfurt 3. Medizinische Klinik

Erfurt, 99089, Germany

Location

Elisabeth-Krankenhaus GmbH Klinik für Kardiologie und Angiologie

Essen, 45138, Germany

Location

Universitätsklinikum Essen (AöR) Westdeutsches Herz- und Gefäßzentrum Essen

Essen, 45147, Germany

Location

Universitätsklinikum Frankfurt ZIM - Med. Klink III - Kardiologie

Frankfurt, 60590, Germany

Location

Klinikum Frankfurt Höchst

Frankfurt Höchst, 65929, Germany

Location

Universitäts-Herzzentrum Freiburg - Bad Krozingen und Innere Medizin III - internistische Intensivmedizin

Freiburg im Breisgau, 79106, Germany

Location

Universitätsklinikum Gießen

Giessen, 35392, Germany

Location

Universitätsmedizin Göttingen Klinik für Kardiologie und Pneumologie

Göttingen, 37075, Germany

Location

Universitätsmedizin Greifswald

Greifswald, 17475, Germany

Location

Universitätsklinikum Halle (Saale) Universitätsklinik und Poliklinik für Innere Medizin III

Halle, 06120, Germany

Location

Asklepios Kliniken Hamburg GmbH

Hamburg, 20099, Germany

Location

Universitätsklinikum Hamburg-Eppendorf Klinik für Kardiologie

Hamburg, 20246, Germany

Location

Universitätsklinikum Heidelberg

Heidelberg, 69120, Germany

Location

SLK-Kliniken Heilbronn GmbH

Heilbronn, 74078, Germany

Location

Universitätsklinikum des Saarlandes Klinik für Innere Medizin III

Homburg, 66421, Germany

Location

Uniklinikum Jena Klinik für Innere Medizin I

Jena, 07747, Germany

Location

Klinikum Kassel GmbH

Kassel, 34125, Germany

Location

Helios Klinikum Krefeld

Krefeld, 47805, Germany

Location

Asklepios Kliniken Langen-Seligenstadt GmbH

Langen, 63225, Germany

Location

Universität Leipzig Klinik und Poliklinik für Kardiologie

Leipzig, 04103, Germany

Location

Herzzentrum Leipzig

Leipzig, Germany

Location

Klinikum der Stadt Ludwigshafen gGmbH

Ludwigshafen, 67063, Germany

Location

Universitäres Herzzentrum Lübeck Medizinische Klinik II (Kardiologie, Angiologie, Intensivmedizin)

Lübeck, 23538, Germany

Location

Universitätsmedizin Mannheim

Mannheim, 68167, Germany

Location

Kliniken Mariahilf GmbH

Mönchengladbach, 41063, Germany

Location

Klinikum Nürnberg

Nuremberg, 90419, Germany

Location

Universitätsklinikum Regensburg Klinik und Poliklinik für Innere Medizin II

Regensburg, 93053, Germany

Location

Kreiskliniken Reutlingen GmbH

Reutlingen, 72764, Germany

Location

Universitätsmedizin Rostock Zentrum für Innere Medizin

Rostock, 18057, Germany

Location

Helios Klinikum Siegburg

Siegburg, 53721, Germany

Location

Universitätsklinikum Ulm Klinik für Innere Medizin II / Kardiologie

Ulm, 89081, Germany

Location

Helios Dr. Horst Schmidt Kliniken Wiesbaden GmbH Klinik Innere MED I: Kardiologie und konserv. Intensivmedizin

Wiesbaden, 65199, Germany

Location

Rems-Murr-Kliniken Winnenden Abteilung für Kardiologie

Winnenden, 71364, Germany

Location

Helios Universitätsklinikum Wuppertal Medizinische Klinik 3 - Kardiologie

Wuppertal, 42117, Germany

Location

Universitätsklinikum Würzburg Medizinische Klinik und Poliklinik I

Würzburg, 97080, Germany

Location

University Medical Centre Ljubljana

Ljubljana, 1000, Slovenia

Location

Related Publications (3)

  • Thevathasan T, Alyahoud M, Freund A, Akin I, Fichtlscherer S, Zeymer U, Feistritzer HJ, Poss J, Jobs A, Rossberg M, Jung C, Skurk C, Rassaf T, Ouarrak T, Schneider S, Thiele H, Desch S. Extracorporeal Membrane Oxygenation Complications Are Not Causal for Mortality in Patients With Infarct-Related Cardiogenic Shock: A Mediation Analysis of the Extracorporeal Life Support in Infarct-Related Cardiogenic Shock (ECLS-SHOCK) Trial. Crit Care Med. 2025 Dec 1;53(12):e2607-e2617. doi: 10.1097/CCM.0000000000006893. Epub 2025 Oct 17.

  • Feistritzer HJ, Zeymer U, Ouarrak T, Akin I, Rassaf T, Lehmann R, Eitel I, Seidler T, Skurk C, Clemmensen P, Voigt I, Seyfarth M, Linke A, Tigges E, Jung C, Lauten P, Poss J, Schneider S, Desch S, Freund A, Thiele H; ECLS-SHOCK Investigators. Different Mechanical Circulatory Support Strategies for Infarct-Related Cardiogenic Shock: A Subanalysis of the ECLS-SHOCK Trial. JACC Cardiovasc Interv. 2025 Mar 24;18(6):691-701. doi: 10.1016/j.jcin.2024.12.010.

  • Thiele H, Zeymer U, Akin I, Behnes M, Rassaf T, Mahabadi AA, Lehmann R, Eitel I, Graf T, Seidler T, Schuster A, Skurk C, Duerschmied D, Clemmensen P, Hennersdorf M, Fichtlscherer S, Voigt I, Seyfarth M, John S, Ewen S, Linke A, Tigges E, Nordbeck P, Bruch L, Jung C, Franz J, Lauten P, Goslar T, Feistritzer HJ, Poss J, Kirchhof E, Ouarrak T, Schneider S, Desch S, Freund A; ECLS-SHOCK Investigators. Extracorporeal Life Support in Infarct-Related Cardiogenic Shock. N Engl J Med. 2023 Oct 5;389(14):1286-1297. doi: 10.1056/NEJMoa2307227. Epub 2023 Aug 26.

MeSH Terms

Conditions

Shock, Cardiogenic

Condition Hierarchy (Ancestors)

Myocardial InfarctionMyocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular DiseasesInfarctionIschemiaPathologic ProcessesPathological Conditions, Signs and SymptomsNecrosisShock

Study Officials

  • Holger Thiele, MD

    Director, Department of Cardiology, Heart Center Leipzig

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 13, 2018

First Posted

August 17, 2018

Study Start

June 20, 2019

Primary Completion

December 23, 2022

Study Completion

September 2, 2024

Last Updated

December 13, 2024

Record last verified: 2024-12

Data Sharing

IPD Sharing
Will not share

Locations